MOJ Cell Science & Report published an editorial written by Circulogene’s Chief Scientific Officer, Dr. Chen-Hsiung Yeh, on Next-Generation Sequencing and Targeted Cancer Therapy.

The complex nature of cancer and the transformation of cancer care, prompted by advanced understanding of genomic subtypes and emergence of targeted therapies, make the detection of genetic alterations to guide therapeutic decision-making more critical than ever. The primary goal of targeted therapies is to fight tumor cells with more precision and potentially fewer side effects. Today, the success of precision cancer therapy is heavily replied on state-of-the-art technologies to identify actionable genetic alterations and monitor dynamic clonal evolutionduring tumor progression to help determine appropriate therapies for cancer patients [1].

Click here to view the full article.